Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences, Cambridge Antibody Form Protein Microarray Alliance: Oct 16, 2000

OXFORD, UK, Sept 12 - Oxford GlycoSciences (LSE: OGS) of Oxfordshire, UK, and Cambridge Antibody Technology (LSE: CAT) of Melbourn, UK, said Tuesday that they are cooperating to develop protein chip technology that will identify proteins by applying antibody-based microarrays.

First OGS’s human protein libraries and CAT’s human antibody libraries will be analyzed so that paired proteins and antibodies can be selected. Then the companies will use OGS’s protein microarray prototype format to develop new microarrays.

The companies want to build a new line of protein detection technology with the speed, throughput, and sensitivity needed to assist the development of research tools, diagnostics, and novel therapeutics. OGS and CAT will fund their respective research contributions.

Michael Kranda, CEO of OGS said, “With the Human Genome map in hand the spotlight has shifted to proteins, proteomics, and antibody technology. The CAT/OGS Protein Chip project will focus on combining our expertise to explore the next generation of high-throughput proteomics technology. We see the field of analytical proteomics maturing similarly to genomics.”  

Kranda added that the alliance will provide access to CAT’s high-throughput antibody technology to shift the OGS prototype microarrays to an industrial scale for developing protein chips as screening and diagnostic tools.  

David Chiswell, CEO of CAT said, “Understanding the expression, processing, modification, and activity of proteins is fundamental to the development of revolutionary diagnostics, prognostics, and therapies for human disease management. We at CAT believe that antibody-based microarrays will be a core tool for unlocking this understanding.”

OGS, a proteomics-based drug discovery and development company, has proteomics collaborations with Bayer, DuPont’s (NYSE: DD) Pioneer Hi-Bred, Merck (NYSE: MRK), and Pfizer (NYSE: PFE). The company also has a joint venture with Incyte Genomics (Nasdaq: INCY).

CAT uses its proprietary technologies in human monoclonal antibodies for drug discovery and development.   Four human therapeutic antibodies developed by CAT are at various stages of clinical trials.

CAT’s has linsing and collaboration deals with Eli Lilly (NYSE: LLY), Pfizer, BASF Pharma, Genentech, ICOS Corporation (Nasdaq: ICOS), Genetics Institute, American Home Product’s (NYSE: AHP) Wyeth-Ayerst Laboratories, Human Genome Sciences (Nasdaq: HGSI), AstraZeneca, and Pharmacia (NYSE: PHA).

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.